No reason to buy, and those who were going to sell have
No reason to buy, and those who were going to sell have already done so.
The LOI is a carrot to encourage folks to buy more shares. However our recent partnering skills and the constant departures of high profile team members have destroyed any credibility for most investors to even take a chance with this company.
Maybe GC can actually come threw for once, but this is a lotto ticket at best.
Goodluck all and hopefully we get good news on Monday and avoid bad news on Friday.
WD
5
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
8x8, Inc. Reports Strong Earnings Amid Growth Initiatives 8x8, Inc. (NASDAQ: EGHT), the prominent cloud communications provider, has experienced a notable uptick of 2% in its share value during after-hours trading following the release of their latest quarterly earnings. The company reported second quarter results that exceeded market expectations, providing a boost in...
Continue Reading
Investors Encouraged to Join Indivior PLC Securities Fraud Lawsuit The Schall Law Firm, a well-known litigation firm dedicated to protecting shareholders' rights, is reaching out to investors about an important class action lawsuit against Indivior PLC (NASDAQ: INDV). This case concerns potential breaches of the Securities Exchange Act of 1934 and Rule 10b-5 as...
Continue Reading
McDermott Strengthens Leadership with New Board Appointments McDermott International, Ltd has made a significant strategic move by announcing the addition of two accomplished professionals, Michael Martino and Farhad Nanji, to its Board of Directors. This change is aimed at bolstering the company’s leadership as it navigates the complex landscapes of the energy...
Continue Reading
United Therapeutics Reaches New Heights in Stock Value United Therapeutics Corporation (NASDAQ: UTHR) has achieved a remarkable milestone by reaching an all-time high of $366.23. This significant increase signifies a robust period of growth for the biotech company, which has seen its stock jump by an impressive 54.22% over the past year. The surge is largely attributed to...
Continue Reading
DoorDash Reaches New Stock Heights DoorDash (NASDAQ: DASH) has experienced a remarkable surge, with its stock recently hitting a 52-week high of $181.78. This leap signifies not only a thriving business model but also a considerable increase in investor confidence in the food delivery service. With a market cap of $75.3 billion, DoorDash has shown impressive growth with a...
Continue Reading
